Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2005 7
2006 10
2007 14
2008 10
2009 21
2010 24
2011 20
2012 25
2013 35
2014 38
2015 45
2016 49
2017 45
2018 34
2019 57
2020 74
2021 86
2022 79
2023 88
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Guo Y, Xue H, Hu N, Liu Y, Sun H, Yu D, Qin L, Shi G, Wang F, Xin L, Sun W, Zhang F, Song X, Li S, Wei Q, Guo Y, Li Y, Liu X, Chen S, Zhang T, Wu Y, Su D, Zhu Y, Xu A, Xu H, Yang S, Zheng Z, Liu J, Yang X, Yuan X, Hong Y, Sun X, Guo Y, Zhou C, Liu X, Wang L, Wang Z. Guo Y, et al. Among authors: su d. J Med Chem. 2024 May 2. doi: 10.1021/acs.jmedchem.4c00027. Online ahead of print. J Med Chem. 2024. PMID: 38695063
Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
Moure CJ, Vara B, Cheng MM, Sondey C, Muise E, Park E, Vela Ramirez JE, Su D, D'Souza S, Yan Q, Yeung CS, Zhang M, Mansueto MS, Linn D, Buchanan M, Foti R, DiMauro E, Long B, Simov V, Barry ER. Moure CJ, et al. Among authors: su d. Mol Cancer Ther. 2024 May 1:OF1-OF14. doi: 10.1158/1535-7163.MCT-23-0538. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38691847
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Guo Y, Yang J, Gong W, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Su D, Chen M. Xu L, et al. Among authors: su d. BMC Med. 2024 Apr 23;22(1):172. doi: 10.1186/s12916-024-03356-5. BMC Med. 2024. PMID: 38650037 Free PMC article. Clinical Trial.
716 results